GlobeNewsWire
03 Sept 2026, 10:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Phase 3 RAPIDe-3 trial subgroup analysis showed deucrictibant IR capsules provided consistent symptom relief, severity reduction, and attack resolution across North American and European/RoW populations. — Positive Phase 3 data across major geographic regions reduces regulatory risk and supports the likelihood of broad market approval for an on-demand HAE treatment.
+0.60Deucrictibant IR capsules were generally well tolerated with no serious treatment-related adverse events reported in the RAPIDe-3 subgroup analysis. — A clean safety profile in late-stage trials is critical for FDA/EMA approval and competitive adoption against existing therapies.
+0.40Non-human primate (NHP) challenge models successfully predicted the human PK/PD relationship and efficacious doses for deucrictibant. — Validating the dosing model increases confidence in the drug's pharmacological predictability but is less market-moving than Phase 3 clinical results.
+0.20Continue reading
6 related stories
Search tags
Proteomic analyses identified over 2,600 proteins with differential abundance in patients with bradykinin-mediated angioedema. — While scientifically valuable for future biomarker discovery, this is a foundational research finding with negligible immediate impact on stock price.
+0.10Which stocks this story touches
The company presented positive clinical and nonclinical data for its drug candidate deucrictibant, including successful Phase 3 regional subgroup analysis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
7h ago
